FDA clears Denali's Avlayah for Hunter syndrome, marking progress for rare disease treatments

The FDA has approved Denali Therapeutics' drug Avlayah for Hunter syndrome, a rare genetic disorder. This approval is seen as a significant advancement following previous regulatory delays and rejections affecting rare disease therapies.